Neurological autoimmunity targeting aquaporin-4.

Area of Science:

• Neuroimmunology
• Autoimmune Diseases
• Central Nervous System (CNS) Disorders

Background:

• Neuromyelitis optica (NMO) is a CNS inflammatory demyelinating disease characterized by specific targeting of aquaporin-4 (AQP4).
• Recent advances have improved understanding of NMO's clinical, radiologic, and immunopathologic features.
• Distinguishing NMO from multiple sclerosis (MS) is crucial for diagnosis and treatment.

Purpose of the Study:

• To review and delineate the key features differentiating CNS AQP4 autoimmunity (NMO) from classical MS.
• To highlight the role of NMO-IgG as a specific biomarker for NMO spectrum disorders.
• To discuss the pathogenic mechanisms initiated by NMO-IgG binding to AQP4.

Main Methods:

• Review of clinical, radiological, and immunopathological data in NMO and MS.
• Analysis of in vitro studies investigating NMO-IgG effects on AQP4 and related pathways.
• Comparison of lesion characteristics and biomarker profiles between NMO and MS.

Main Results:

• NMO preferentially affects optic nerves and spinal cord, though initial attacks in children may involve the brain.
• NMO-IgG, an AQP4-specific autoantibody, serves as a reliable biomarker for NMO spectrum disorders.
• NMO lesions show distinct features including loss of AQP4 and EAAT2, complement deposition, prominent edema, and inflammation, differing from MS lesions.

Conclusions:

• NMO spectrum disorders are distinct from MS, driven by AQP4 autoimmunity.
• NMO-IgG plays a central role in NMO pathogenesis through multiple neuropathogenic mechanisms.
• Development of effective therapies necessitates validated animal and cell culture models for NMO.